Amgen reports data from Sjögren’s Syndrome treatment trial

Sly Saint · Nov 8, 2023

Treatment with dazodalibep was found to be safe and well tolerated in both subject groups in the trial.

Amgen has reported the latest findings from its Phase II clinical trial of the investigational medicine, dazodalibep, to treat patients with Sjögren’s syndrome, an autoimmune disease.

The placebo-controlled, double-blind, randomised, crossover trial is designed to analyse dazodalibep in two Sjögren’s populations.

These groups included subjects with moderate to severe systemic disease activity, as well as people with moderate to severe symptomatology but no further organ involvement.

According to the latest trial findings, dazodalibep was shown to offer an improvement in systemic and symptomatic disease burden in these subject groups.

The treatment was found to be safe and well-tolerated in both groups.

In May 2023, the company reported that both patient populations who received treatment with dazodalibep met the primary endpoint at day 169.

Amgen research and development executive vice-president David Reese said: “To date, there are no FDA-approved disease-modifying treatments for Sjögren’s and the positive results from the Phase II trial provide evidence that dazodalibep may address the underlying causes of the disease by reducing systemic disease activity and improving the debilitating symptoms, such as dryness and fatigue.”

A CD40 ligand antagonist, dazodalibep is presently being evaluated in a Phase III trial in patients with Sjögren’s.
Click to expand...

Amgen reports data from Sjögren’s Syndrome treatment trial (clinicaltrialsarena.com)

Log in or Sign up

Amgen reports data from Sjögren’s Syndrome treatment trial

Sly Saint Senior Member (Voting Rights)

Share This Page

Log in or Sign up

Amgen reports data from Sjögren’s Syndrome treatment trial

Sly Saint Senior Member (Voting Rights)

Share This Page

Useful Searches